Hu Yue, Yang Liang, Lu Yunfei, Wang Yong, Jiang Jianshuai, Liu Yahui, Cao Qing
Department of Hepatobiliary and Pancreatic Surgery, Ningbo First Hospital, Ningbo, Zhejiang, China.
Medical Record Statistics Department, Ningbo First Hospital, Ningbo, Zhejiang, China.
Evid Based Complement Alternat Med. 2022 Sep 20;2022:2116006. doi: 10.1155/2022/2116006. eCollection 2022.
Traditional Chinese medicine (TCM) sometimes plays a crucial role in advanced cancer treatment. Despite the significant therapeutic efficacy in hepatocellular carcinoma (HCC) that Planch root extract (acRoots) has proven, its complex composition and underlying mechanism have not been fully elucidated. Therefore, this study analyzed the multiple chemical compounds in acRoots and their targets via network pharmacology and bioinformatics analysis, with the overarching goal of revealing the potential mechanisms of the anti-HCC effect.
The main ingredients contained in acRoots were initially screened from the traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), and the candidate bioactive ingredient targets were identified using DrugBank and the UniProt public databases. Second, the biological processes of the targets of active molecules filtered from the ingredients of acRoots were evaluated using gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Third, weighted gene coexpression network analysis (WGCNA) was performed to identify gene coexpression modules associated with HCC. The hub genes of acRoots in HCC were defined via contrasting the above module eigengenes with candidate target genes of acRoots. Furthermore, the target-pathway network was analyzed to explore the mechanism for anti-HCC effect of hub genes. Kaplan-Meier plotter database analysis was performed to validate the hub genes of acRoots correlation with prognostic values in HCC. In order to verify the results of the network pharmacological analysis, we performed a molecular docking approach on the active ingredients and key targets using the Discovery Studio software. The viability of SMMC-7721 and HL-7702 cells was determined by Cell counting kit-8 (CCK-8) after being treated with different concentrations of (+)-catechin (0, 50, 100, 150, 200, and 250 g/ml) for 24, 48, and 72 hours, respectively. Finally, qRT-PCR and Western blot involving human hepatocarcinoma cells were utilized to verify the impact of (+)-catechin on the hub genes associated with prognosis.
6 out of 26 active ingredients extracted from TCMSP were deemed as the core ingredients of acRoots. 175 bioactive-ingredient targets of acRoots were obtained and a bioactive-ingredient targets network was established correspondingly. The biological processes (BP) of target genes mainly involved processes, such as toxic substance and wounding. The results of KEGG pathways indicated that the target genes were mainly enriched in pathways in cancer, AGE-RAGE signaling pathway in diabetic complications, IL-17 signaling pathway, and other pathways. Also, the two hub genes (i.e., ESR1 and CAT) were closely associated with the prognosis of HCC patients. As a consequence, we predicated a series of signaling pathways, including estrogen signaling pathway and longevity regulation pathway, through which acRoots could facilitate the treatment for HCC. The molecular docking experiment ascertained that ESR1 and CAT had an effective binding force with (+)-catechin, one of the core ingredients of acRoots. Furthermore, (+)-catechin inhibited SMMC-7721 cell growth in a dose-dependent manner and a time-dependent manner. Finally, we suggest that the expression level of ESR1 and CAT is positively related to the (+)-catechin concentrations in in-vitro experiments.
The bioactive ingredients of acRoots, including quercetin, (+)-catechin, beta-sitosterol, and aloe-emodin, have synergistic interactions in reinforcing the anticancer effect in HCC. Evidently, acRoots took effect by regulating multitargets and multipathways through its active ingredients. Further, (+)-catechin, the possible paramount anti-HCC active ingredient in acRoots, helped improve the prognosis of HCC patients by increasing the expression of ESR1 and CAT. Additionally, the findings yielded provide a conceptual guidance for the clinical treatment of HCC and the methods adopted are potentially applicable in the future comprehensive analysis of the underlying mechanisms of TCMs.
中医(TCM)在晚期癌症治疗中有时起着关键作用。尽管虎杖根提取物(acRoots)已被证明对肝细胞癌(HCC)具有显著的治疗效果,但其复杂的成分和潜在机制尚未完全阐明。因此,本研究通过网络药理学和生物信息学分析,分析了acRoots中的多种化学成分及其靶点,旨在揭示其抗HCC作用的潜在机制。
首先从中医系统药理学数据库及分析平台(TCMSP)中筛选出acRoots所含的主要成分,并利用DrugBank和UniProt公共数据库鉴定候选生物活性成分靶点。其次,使用基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路分析,评估从acRoots成分中筛选出的活性分子靶点的生物学过程。第三,进行加权基因共表达网络分析(WGCNA),以识别与HCC相关的基因共表达模块。通过将上述模块特征基因与acRoots的候选靶基因进行对比,确定acRoots在HCC中的枢纽基因。此外,分析靶标-通路网络,以探索枢纽基因抗HCC作用的机制。利用Kaplan-Meier plotter数据库分析验证acRoots枢纽基因与HCC预后价值的相关性。为了验证网络药理学分析的结果,我们使用Discovery Studio软件对活性成分和关键靶点进行了分子对接。用不同浓度的(+)-儿茶素(0、50、100、150、200和250μg/ml)分别处理SMMC-7721和HL-7702细胞24、48和72小时后,通过细胞计数试剂盒-8(CCK-8)测定细胞活力。最后,利用涉及人肝癌细胞的qRT-PCR和蛋白质印迹法,验证(+)-儿茶素对与预后相关的枢纽基因的影响。
从TCMSP中提取出的26种活性成分中有六种被视为acRoots的核心成分。获得了acRoots的175个生物活性成分靶点,并相应建立了生物活性成分靶点网络。靶基因的生物学过程(BP)主要涉及诸如有毒物质和损伤等过程。KEGG通路结果表明,靶基因主要富集于癌症通路、糖尿病并发症中的AGE-RAGE信号通路、IL-17信号通路等通路。此外,两个枢纽基因(即ESR1和CAT)与HCC患者的预后密切相关。因此,我们预测了一系列信号通路,包括雌激素信号通路和寿命调控通路,acRoots可通过这些通路促进HCC的治疗。分子对接实验确定ESR1和CAT与acRoots的核心成分之一(+)-儿茶素具有有效的结合力。此外,(+)-儿茶素以剂量依赖和时间依赖的方式抑制SMMC-7721细胞生长。最后,我们发现在体外实验中ESR1和CAT的表达水平与(+)-儿茶素浓度呈正相关。
acRoots的生物活性成分,包括槲皮素、(+)-儿茶素、β-谷甾醇和芦荟大黄素,在增强HCC抗癌作用方面具有协同相互作用。显然,acRoots通过其活性成分调节多靶点和多通路发挥作用。此外,(+)-儿茶素可能是acRoots中最重要的抗HCC活性成分,通过增加ESR1和CAT的表达有助于改善HCC患者的预后。此外,本研究结果为HCC的临床治疗提供了理论指导,所采用的方法可能适用于未来对中药潜在机制的综合分析。